32.32
price up icon0.09%   0.03
after-market アフターアワーズ: 32.32
loading
前日終値:
$32.29
開ける:
$32.29
24時間の取引高:
562.29K
Relative Volume:
0.69
時価総額:
$2.09B
収益:
$32.08M
当期純損益:
$-169.77M
株価収益率:
-11.37
EPS:
-2.8418
ネットキャッシュフロー:
$-147.70M
1週間 パフォーマンス:
+0.59%
1か月 パフォーマンス:
+10.31%
6か月 パフォーマンス:
-8.96%
1年 パフォーマンス:
+65.24%
1日の値動き範囲:
Value
$31.16
$32.76
1週間の範囲:
Value
$29.86
$33.43
52週間の値動き範囲:
Value
$18.00
$40.22

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
名前
Stoke Therapeutics Inc
Name
セクター
Healthcare (1033)
Name
電話
781-430-8200
Name
住所
45 WIGGINS AVENUE, BEDFORD, MA
Name
職員
170
Name
Twitter
@stoketx
Name
次回の収益日
2026-08-11
Name
最新のSEC提出書
Name
STOK's Discussions on Twitter

Compare STOK vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
STOK icon
STOK
Stoke Therapeutics Inc
32.32 2.03B 32.08M -169.77M -147.70M -2.8418
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
547.59 136.93B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
828.50 85.11B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
1,011.11 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
138.89 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
211.58 45.38B 742.00K -1.37B -1.07B -7.0731

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-02-05 開始されました Guggenheim Buy
2026-01-05 再開されました Chardan Capital Markets Buy
2025-07-18 開始されました Jefferies Buy
2024-12-20 開始されました Chardan Capital Markets Buy
2024-10-14 再開されました Leerink Partners Outperform
2024-03-26 アップグレード TD Cowen Market Perform → Outperform
2023-11-20 再開されました JP Morgan Neutral
2023-07-25 ダウングレード TD Cowen Outperform → Market Perform
2023-05-01 アップグレード BofA Securities Underperform → Neutral
2023-04-26 再開されました Canaccord Genuity Buy
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2022-10-24 アップグレード SVB Leerink Mkt Perform → Outperform
2022-01-31 開始されました Jefferies Buy
2021-12-03 開始されました BofA Securities Buy
2021-11-22 アップグレード JP Morgan Neutral → Overweight
2021-05-18 開始されました UBS Neutral
2021-05-10 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-02-10 ダウングレード Wedbush Outperform → Neutral
2020-12-15 再開されました H.C. Wainwright Buy
2020-12-11 繰り返されました Needham Buy
2020-10-23 開始されました Cantor Fitzgerald Overweight
2020-09-29 再開されました JP Morgan Neutral
2020-09-29 開始されました Needham Buy
2019-12-18 開始されました Wedbush Outperform
2019-11-12 開始されました BTIG Research Buy
2019-10-25 開始されました H.C. Wainwright Buy
2019-07-15 開始されました Canaccord Genuity Buy
2019-07-15 開始されました Cowen Outperform
2019-07-15 開始されました Credit Suisse Outperform
2019-07-15 開始されました JP Morgan Overweight
すべてを表示

Stoke Therapeutics Inc (STOK) 最新ニュース

pulisher
Aug 21, 2026

STOK Reinstated by JP Morgan -- Price Target Set at $40 - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat

Aug 21, 2026
pulisher
Aug 21, 2026

Goldminenunternehmen, Ross Stores, Stoke Therapeutics - TradingView

Aug 21, 2026
pulisher
Aug 21, 2026

STOK Looks 225.6% Overvalued on GF Value™ - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

Why is Stoke Therapeutics stock gaining today? By Investing.com - Investing.com Canada

Aug 21, 2026
pulisher
Aug 21, 2026

Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Yahoo Finance

Aug 21, 2026
pulisher
Aug 20, 2026

Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9%What's Next? - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Stoke (STOK) Results Breakdown: The Available Earnings Metric Delivers a Miss in the Reported Period; Share Response: The Stock Records a 2.77% Increase in the Latest ReadingPerformance Review - Vinanet

Aug 20, 2026
pulisher
Aug 19, 2026

Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)? - simplywall.st

Aug 19, 2026
pulisher
Aug 19, 2026

Stoke (STOK) Quarterly Figures: EPS Falls Short of Its Estimate for the Current Session; Share Move: The Stock Gains 2.64% in the Current UpdateLow Estimate Range - Vinanet

Aug 19, 2026
pulisher
Aug 19, 2026

Stoke Therapeutics general counsel Allan sells $91,639 in stock By Investing.com - Investing.com Australia

Aug 19, 2026
pulisher
Aug 18, 2026

Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com - Investing.com Australia

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics’ director Kaye sells $402,528 in shares By Investing.com - Investing.com Australia

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics general counsel Allan sells $91,639 in stock - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics’ director Kaye sells $402,528 in shares - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke therapeutics CMO Barry Ticho sells $152k in stock - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 4,767 Shares of Stock - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics (STOK) insider sale tied to tax withholding - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics (NASDAQ: STOK) CMO gets 10,000 shares, sells some for taxes - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics (STOK) director share sale tied to taxes - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke (STOK) Session-Level Review: Closes 0.70% Higher at $32.35 on the Day; Nearby Levels: Price Remains Between $30.73 Support and $33.97 Resistance on the DayEarnings Beat Stocks - Vinanet

Aug 18, 2026
pulisher
Aug 17, 2026

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts - TradingView

Aug 17, 2026
pulisher
Aug 14, 2026

Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Trading Systems Reacting to (STOK) Volatility - Stock Traders Daily

Aug 14, 2026
pulisher
Aug 13, 2026

Stoke Therapeutics (STOK) Slips 0.99% to $32.65 as Shares Consolidate Between Key Support and ResistanceWeak Sell Signals - Vinanet

Aug 13, 2026
pulisher
Aug 12, 2026

Stoke Therapeutics (STOK): TD Bank, TD Securities disclose 4.9% equity stake - Stock Titan

Aug 12, 2026
pulisher
Aug 12, 2026

Stoke Therapeutics at canaccord growth conference: trial momentum builds By Investing.com - Investing.com Canada

Aug 12, 2026
pulisher
Aug 12, 2026

Stoke Therapeutics at canaccord growth conference: trial momentum builds - Investing.com

Aug 12, 2026
pulisher
Aug 11, 2026

Stoke Therapeutics (STOK) Short Interest & Short Float | Updated Aug 2026 $STOK - MarketBeat

Aug 11, 2026
pulisher
Aug 10, 2026

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 10, 2026
pulisher
Aug 09, 2026

Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A. - MarketBeat

Aug 09, 2026
pulisher
Aug 08, 2026

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The National Law Review

Aug 08, 2026
pulisher
Aug 07, 2026

Stoke Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-08-07 - Seeking Alpha

Aug 07, 2026
pulisher
Aug 07, 2026

Stoke Therapeutics Inc (STOK) Stock News Today - TradingKey

Aug 07, 2026
pulisher
Aug 07, 2026

Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 43.5% Upside In Biotech's Genetic Revolution - DirectorsTalk Interviews

Aug 07, 2026
pulisher
Aug 07, 2026

What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? - Yahoo Finance

Aug 07, 2026
pulisher
Aug 06, 2026

FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A - Stock Titan

Aug 06, 2026
pulisher
Aug 06, 2026

Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report - simplywall.st

Aug 06, 2026
pulisher
Aug 06, 2026

Q3 EPS Estimates for Stoke Therapeutics Cut by HC Wainwright - MarketBeat

Aug 06, 2026
pulisher
Aug 05, 2026

Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan - Stock Titan

Aug 05, 2026
pulisher
Aug 05, 2026

A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60 - Moomoo

Aug 05, 2026
pulisher
Aug 05, 2026

Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK) - Seeking Alpha

Aug 05, 2026
pulisher
Aug 05, 2026

Stoke Therapeutics CMO Barry Ticho disposes of USD 208,707 in common shares - Bitget

Aug 05, 2026
pulisher
Aug 05, 2026

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - marketscreener.com

Aug 05, 2026
pulisher
Aug 05, 2026

Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

STOK Maintained by Canaccord Genuity -- Price Target Lowered to $58 - GuruFocus

Aug 05, 2026
pulisher
Aug 04, 2026

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results - webull.com

Aug 04, 2026
pulisher
Aug 04, 2026

STOK Maintains Rating by Wedbush -- Price Target Raised to $40 - GuruFocus

Aug 04, 2026

Stoke Therapeutics Inc (STOK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$123.98
price up icon 0.00%
$61.33
price up icon 0.03%
$112.82
price down icon 3.22%
$236.01
price down icon 0.09%
ONC ONC
$371.98
price down icon 0.66%
$211.58
price up icon 1.01%
大文字化:     |  ボリューム (24 時間):